INTRODUCTION {#s1}
============

The *anaplastic lymphoma kinase (ALK)* gene is rearranged in approximately 5% of non-small-cell lung cancer (NSCLC) cases, leading to constitutive activation of the ALK tyrosine kinase domain and tumorigenesis \[[@R1], [@R2]\]. Crizotinib is an inhibitor of ALK kinase activity that has demonstrated its superiority over conventional chemotherapy in advanced *ALK*-positive NSCLC \[[@R3], [@R4]\]. Crizotinib was compared to standard first-line and second-line chemotherapy in two randomized Phase III trials (PROFILE 1014 and PROFILE 1007), achieving higher response rates and a significantly longer median progression-free survival (PFS) \[[@R3], [@R4]\]. It is now approved worldwide for treating advanced *ALK*-positive NSCLC.

The estimation of overall survival (OS) with crizotinib has not yet been fully documented. A retrospective analysis comparing 30 crizotinib-treated *ALK*-positive NSCLC patients to 23 crizotinib-naïve ones reported longer OS in the former (1-year OS: 70% *vs*. 44%; 2-year OS: 55% *vs*. 12%, respectively) \[[@R5]\]. In the PROFILE 1007 trial comparing crizotinib to pemetrexed or docetaxel as second-line following platinum-based regimen failure, an updated survival analysis showed a median OS with crizotinib at 21.7 months but identified no difference in OS between the crizotinib arm and chemotherapy arm, probably due to a cross-over in the chemotherapy arm \[[@R6]\]. Another limitation comes from the restrictive inclusion criteria implemented in clinical trials, meaning any benefit observed in a selected population might not reflect that in daily practice.

Most patients experience progressive disease (PD) within one year of crizotinib initiation \[[@R3], [@R4]\]. Locally-ablative treatment could extend disease control with crizotinib in oligoprogressive disease \[[@R7], [@R8]\], and continuing crizotinib beyond PD (CBPD) might favourably impact survival outcomes \[[@R9]\]. Anecdotal clinical response to crizotinib rechallenge has been reported \[[@R10], [@R11]\]. The efficacy of conventional chemotherapy is debatable as very little clinical data is available after crizotinib failure \[[@R12]\].

Next-generation ALK inhibitors (ALKis) can overcome resistance to crizotinib. Ceritinib has proven efficacious in crizotinib-pretreated patients in a dose escalation Phase I trial (response rate: 56%; median PFS: 6.9 months), and has been approved by both FDA and EMA following crizotinib failure \[[@R13], [@R14]\]. Alectinib is also effective in crizotinib-pretreated patients (response rate: 48-55%; PFS: 8.1-8.9 months) and FDA approved \[[@R15]--[@R17]\]. Other promising next-generation ALKis are under clinical investigation \[[@R18], [@R19]\]. Given their efficacy, a potential survival benefit associated with using next-generation ALKi following crizotinib failure has been suspected, though not yet proven, in comparison with other systemic treatment options \[[@R20]--[@R22]\].

The IFCT-1302 CLINALK study sought to evaluate OS under crizotinib in a large unselected population of *ALK*-positive NSCLC patients. We also aimed to examine the different systemic treatments' effect on survival following crizotinib and whether next-generation ALKis improve survival outcomes in this setting.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

In total, 318 patients were selected for data collection and analysis (Figure [1](#F1){ref-type="fig"}). Of them, 214 met the inclusion criteria in the French crizotinib expanded access program (EAP) database. Following EAP discontinuation, 104 additional *ALK*-positive patients treated with crizotinib as second-line approved drug were enrolled.

![Study flow chart](oncotarget-08-21903-g001){#F1}

Table [1](#T1){ref-type="table"} presents the patients' characteristics on initiating crizotinib. Half were male, the median age was under 60 years old, and the majority had never smoked and presented with adenocarcinomas. One third exhibited brain metastasis, and 77.3% PS 0 or 1.

###### Baseline characteristics for the population at the time of crizotinib initiation

  Characteristics, n (%)              N=318
  ----------------------------------- -------------------
  Age, years                          
   Median (range)                     58.3 (19.2--88.4)
   \<65                               221 (69.5%)
   ≥65                                97 (30.5%)
  Gender                              
   Male                               161 (50.6%)
   Female                             157 (49.4)
  Ethnicity                           
   Non-Asian                          294 (98.3%)
   Asian                              5 (1.7%)
   MD                                 19
  Smoking status                      
   Current-smoker                     29 (9.4%)
   Former-smoker                      108 (34.8%)
   Never-smoker                       173 (55.8%)
   MD                                 8
  Histology                           
   Adenocarcinoma                     292 (91.8%)
   Large cell                         19 (6.0%)
   Other                              7 (2.2%)
  ECOG PS                             
   0                                  92 (31.6%)
   1                                  133 (45.7%)
   2                                  43 (14.8%)
   3                                  21 (7.2%)
   4                                  2 (0.7%)
   MD                                 27
  Stage at diagnosis                  
   Localized                          5 (1.6%)
   Locally-advanced                   45 (14.1%)
   Metastatic                         268 (84.3%)
  Brain metastasis                    
   Yes                                111 (34.9%)
   No                                 207 (65.1%)
  Line of therapy before crizotinib   
   0                                  16 (5.0%)
   1                                  172 (54.1%)
   ≥2                                 130 (40.9%)

MD = missing data; ECOG PS = Eastern Cooperative Oncology Group performance status.

One hundred seventy-two patients (54.1%) received crizotinib as second-line treatment, 16 (5.0%) were treated in the front-line setting, 59 (18.6%) in third-line, and 71 (22.3%) in fourth- or further-line setting. The mean time from diagnosis of advanced disease to initiating crizotinib treatment was 13.9 months (95% CI: 12.4-15.5). Platinum- and pemetrexed-based chemotherapy were administered before crizotinib to 277 (91.7%) and 244 (80.8%) patients, respectively.

Crizotinib efficacy {#s2_2}
-------------------

Disease progression was observed in 284 patients (89.3%) by the time of data cut-off. The median PFS under crizotinib was 6.8 months (95% CI: 5.6-8.3). Of the 267 evaluable patients, one complete response (0.4%) and 133 partial responses (49.8%) were reported for an ORR of 50.2% (95% CI: 44.2-56.2). The DCR was 74.9% (95% CI: 69.7-80.1). At time of the analysis, 39 patients were still receiving crizotinib.

Analysis of overall survival with crizotinib {#s2_3}
--------------------------------------------

We lost 14 patients (4.4%) to follow-up. By the time of the analysis, 209 patients (65.7%) had died. The median duration of follow-up was 44.4 months (95% CI: 40.6-47.5). The median OS from diagnosis of metastatic disease was 30.9 months (95% CI: 26.7-34.5).

The median OS from first crizotinib dose was 16.6 months (95% CI: 12.2-19.6) (Figure [2](#F2){ref-type="fig"}). The 6- and 12-month survival rates were 73.4% (95% CI: 68.5-78.3) and 56.2% (95% CI: 50.7-61.7), respectively. After adjusting for potential confounding factors, multivariable Cox regression (Table [2](#T2){ref-type="table"}) revealed former- or never-smoker status on crizotinib initiation, adenocarcinoma histology, and PS 0-1 to be significantly associated with decreased risk of death. Median OS was significantly longer for patients with PS 0-1 than those with PS 2-4 (19.5 months \[95% CI: 16.5-25.0\] versus 4.5 months \[95% CI: 3.0-7.3\], log rank p \<0.001). The line of crizotinib therapy did not impact OS (Table [2](#T2){ref-type="table"}).

![Overall survival from the first crizotinib dose](oncotarget-08-21903-g002){#F2}

###### Cox proportional hazard ratio analysis of overall survival from the first crizotinib dose

                                                Tested           Reference            Univariable analysis   Multivariable analysis                       
  --------------------------------------------- ---------------- -------------------- ---------------------- ------------------------ ------------------- ---------
  Age                                           \< median        ≥ median             0.97 (0.74--1.27)      0.81                                         
  Gender                                        Female           Male                 0.99 (0.75--1.29)      0.93                                         
  Smoking status                                Never            Former/current       0.79 (0.60--1.03)      0.09                     (--)                NS
  Current smoker                                No               Yes                  0.45 (0.30--0.69)      \<0.001                  0.44 (0.29--0.67)   \<0.001
  Histology                                     Adenocarcinoma   Non-adenocarcinoma   0.64 (0.40--1.02)      0.06                     0.59 (0.36--0.97)   0.04
  PS                                            0-1              2-4                  0.36 (0.27--0.50)      \<0.001                  0.35 (0.26--0.48)   \<0.001
  Stage                                         III              IV                   0.84 (0.56--1.26)      0.40                                         
  Brain metastasis                              No               Yes                  0.95 (0.71--1.25)      0.70                                         
  Number of treatment lines before crizotinib   0-1              ≥2                   0.79 (0.60--1.04)      0.09                     (--)                NS
  Setting of administration                     EMA approval     EAP                  0.86 (0.63--1.17)      0.33                                         

HR = hazard ratio; CI = confidence interval; PS = performance status; EMA = European Medicines Agency; EAP = expanded access program; NS = not significant.

Effect on overall survival of systemic treatments following progression on crizotinib {#s2_4}
-------------------------------------------------------------------------------------

Disease progression on crizotinib was documented in 284 patients. To avoid an immortal time bias and the inclusion in survival analysis of patient who could not receive subsequent treatments after crizotinib, the 21 patients who died under crizotinib were not considered for the survival analysis of systemic treatments following progression on crizotinib. Finally, a population of 263 with documented progressive disease was considered.

The sites of progression are provided in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, including 99 cases (37.6%) of cerebral progression, regardless of the extra-cerebral status. There were 136 (51.7%) oligoprogressive diseases, 60 (44.1%) of which occurred in the brain.

CBPD was documented in 86 patients (32.7%). The median duration of CBPD was 6.6 months (range: 0.7-35.2). The baseline characteristics and progression patterns of CBPD and non-CBPD patients are provided in Table [3](#T3){ref-type="table"}. Patients under 65 years, with PFS on crizotinib ≥median, cerebral progression, and oligoprogression were more common in the CBPD population. This population was more commonly treated with next-generation ALKis following disease progression. The median OS from the first crizotinib dose was significantly longer in CBPD patients than in non-CBPDs (32.2 months \[95% CI: 25.4-NR\] versus 11.2 months \[95% CI: 8.4-12.9\]; log rank p \<0.0001), as was median post-PD survival (18.7 months \[95% CI: 15.1-26.9\] versus 4.0 months \[95% CI: 3.0-5.6\]; log rank p \<0.0001).

###### Baseline and post-progression characteristics of the patients who continued crizotinib beyond progressive disease and those who did not

  Characteristics                                         n (%)               *P*-value^a^                            
  ------------------------------------------------------- ------------------- ------------------- ------------------- -----------
  Age, years                                                                                                          
   Median (range)                                         56.48 (19.2-88.4)   54.83 (19.2-86.8)   58.08 (25.2-88.4)   0.10^b^
   \<65                                                   194 (73.8)          71 (83)             123 (69.5)          
   ≥65                                                    69 (26.2)           15 (17)             54 (30.5)           0.02^c^
  Gender                                                                                                              
   Male                                                   136 (51.7)          49 (57)             87 (49.2)           0.23^c^
   Female                                                 127 (48.3)          37 (43)             90 (50.8)           
  Ethnicity                                                                                                           
   Non-Asian                                              241 (91.6)          79 (92)             162 (91.5)          0.28^d^
   Asian                                                  5 (1.9)             3 (4)               2 (1.1)             
   MD                                                     17 (6.5)            4 (6)               13 (7.3)            
  Smoking status at baseline                                                                                          
   Current-smoker                                         26 (10.0)           4 (5)               22 (12.7)           0.09^c^
   Former-smoker                                          88 (34.0)           28 (33)             60 (34.7)           
   Never-smoker                                           145 (56.0)          54 (63)             91 (52.6)           
   MD                                                     4                   0                   4                   
  Tumour histological type                                                                                            
   Adenocarcinoma                                         241 (91.6)          83 (96)             158 (89.3)          0.06^d^
   Non-adenocarcinoma^d^                                  22 (8.4)            3 (4)               19 (10.7)           
   MD                                                     0                   0                   0                   
  PS at baseline                                                                                                      
   0-1                                                    192 (78.7)          61 (80)             131 (78.0)          0.69^c^
   2-4                                                    52 (21.3)           15 (20)             37 (22.0)           
   MD                                                     19                  10                  9                   
  Stage at diagnosis                                                                                                  
   I/II                                                   3 (1.1)             2 (2)               1 (0.6)             0.16^d^
   Metastatic                                             224 (85.2)          75 (87)             149 (84.2)          
   Locally advanced                                       36 (13.7)           9 (11)              27 (15.3)           
   MD                                                     0                   0                   0                   
  Brain metastasis at baseline                                                                                        
   Yes                                                    95 (36.1)           31 (36)             64 (36.2)           0.99^c^
   No                                                     168 (63.9)          55 (64)             113 (63.8)          
   MD                                                     0                   0                   0                   
  Lines of therapy before crizotinib                                                                                  
   0-1                                                    157 (59.7)          52 (60)             105 (59.3)          0.86^c^
   ≥2                                                     106 (40.3)          34 (40)             72 (40.7)           
  Cerebral progression                                                                                                
   Yes                                                    99 (37.6)           48 (56)             51 (28.8)           \<.001^c^
   No                                                     164 (62.4)          38 (44)             126 (71.2)          
  Oligoprogression                                                                                                    
   Yes                                                    136 (51.7)          61 (71)             75 (42.4)           \<.001^c^
   No                                                     127 (48.3)          25 (29)             102 (57.6)          
  PFS with crizotinib                                                                                                 
   ≥median                                                126 (47.9)          59 (69)             67 (37.9)           \<.001^c^
   \<median                                               137 (52.1)          27 (31)             110 (62.1)          
  Subsequent treatment after progression on crizotinib                                                                
   Yes                                                    158 (60.1)          50 (58)             108 (61.0)          0.65^c^
   No                                                     105 (39.9)          36 (42)             69 (39.0)           
  Next-generation ALKis after progression on crizotinib                                                               
   Yes                                                    84 (31.9)           36 (41.9)           48 (27.1)           0.02^c^
   No                                                     105 (39.9)          50 (58.1)           129 (72.9)          

CBPD = crizotinib beyond progressive disease; MD = missing data; PS = performance status; PFS = progression-free survival; ALKi = ALK inhibitor.

^a^Continued CBPD versus did not continue CBPD.

^b^Student\'s t-test of comparison of the mean.

^c^Chi-squared test of general association.

^d^Fisher\'s exact test of general association when sample size requirement for chi-squared test was not matched.

^e^Includes large-cell and other types of carcinoma.

The drugs administered as first-line and second-line post-crizotinib are shown in Table [4](#T4){ref-type="table"} (full details in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The next-generation ALKis administered were ceritinib for 57 patients, alectinib for 19, ceritinib then alectinib for five, ceritinib then lorlatinib in one, and alectinib then ceritinib in two. Crizotinib was rechallenged in nine (3.4%). Chemotherapy was combined with ALKis in eight. Twenty patients received unmonitored subsequent systemic treatment after second-line post-PD: 10 in the group receiving next-generation ALKis and 10 in the group receiving subsequent drugs other than next-generation ALKi.

###### Drugs used in first-line and second-line post-disease progression on crizotinib in patients receiving subsequent drugs other than next-generation ALKis and patients receiving next-generation ALKis

  Drugs used (n)                  First-line post-PD on crizotinib   Second-line post-PD on crizotinib             
  ------------------------------- ---------------------------------- ----------------------------------- --------- ---------
  Chemotherapy (n, %)             49 (66)                            12 (14)                             25 (61)   14 (33)
   Platinum-based                 16                                 3                                   5         3
   Pemetrexed-based               20                                 7                                   7         4
   Taxane-based                   18                                 4                                   11        8
   Other                          7                                  1                                   7         2
  ALKi (n, %)                     10 (14)                            69 (82)                             11 (27)   24 (57)
   Ceritinib                      \_                                 49                                  \_        15
   Alectinib                      \_                                 19                                  \_        7
   Lorlatinib                     \_                                 \_                                  \_        1
   Crizotinib                     7                                  1                                   11        \_
   Crizotinib and anti-HSP90      3                                  3                                   \_        1
  Chemotherapy and ALKis (n, %)   7 (9)                              0 (0)                               2 (5)     1 (3)
  Others (n, %)                   8 (11)                             3 (4)                               3 (7)     3 (7)
   Erlotinib                      4                                  \_                                  3         \_
   Anti-HSP90                     3                                  3                                   \_        1
   Pembrolizumab                  \_                                 \_                                  \_        2
   Anti-MET                       1                                  \_                                  \_        \_

PD = progressive disease; ALKi = ALK inhibitor.

In order to analyse the effect different systemic treatments have on survival following progression on crizotinib, the patients were separated into three groups: best supportive care (BSC) only (n=105, 40%), subsequent drugs other than next-generation ALKis (n=74, 28.1%), and next-generation ALKis (n=84, 31.9%). The characteristics at baseline and time of disease progression are provided in Table [5](#T5){ref-type="table"}. Patients receiving BSC only were older, had poorer PS, were heavily pretreated, and more frequently exhibited PFS on crizotinib \<median than those receiving subsequent drugs. Patients receiving next-generation ALKis were younger, more frequently exhibited PFS on crizotinib ≥median, more frequently received CBPD, and more frequently exhibited cerebral progression than patients receiving subsequent drugs other than next-generation ALKis.

###### Characteristics at baseline and at time of progression on crizotinib, according to systemic treatment strategies after progression on crizotinib

  Characteristics                            n (%)       P-value      n (%)        *P*-value             
  ------------------------------------------ ----------- ------------ ------------ ----------- --------- ------------
  **Baseline**                                                                                           
  Age ≥ 65 years                             36 (34.3)   33 (20.9)    0.02^b^      21 (28)     12 (14)   0.03^b^
  Gender, male                               53 (50.5)   83 (52.5)    0.74^b^      40 (54)     43 (51)   0.72^b^
  Smoking status                                                      0.12^b^                            0.73^b^
   Current-smoker                            15 (14.3)   11 (7.1)                  6 (8)       5 (6)     
   Former-smoker                             31 (29.5)   57 (37.0)                 28 (39)     29 (35)   
   Never-smoker                              59 (56.2)   86 (55.9)                 38 (53)     48 (59)   
  Non-adenocarcinoma histology^d^            12 (11.4)   10 (6.3)     0.14^b^      8 (11)      2 (2)     0.05^c^
  PS 2-4                                     37 (35.3)   15 (9.5)     \<0.001^b^   10 (14)     5 (7)     0.17^b^
  Metastatic stage                           90 (85.7)   134 (84.8)   0.99^c^      62 (84)     72 (86)   0.85^c^
  Brain metastasis                           33 (31.4)   62 (39.2)    0.20^b^      26 (35)     36 (43)   0.32^b^
  PFS with crizotinib \<median               75 (71.4)   62 (39.2)    \<0.001^b^   40 (54)     22 (26)   \<0.001^b^
  ≥2 lines before crizotinib                 52 (49.5)   54 (34.2)    0.01^b^      27 (37)     27 (32)   0.57^b^
  **At time of progression on crizotinib**                                                               
  Cerebral progression                       38 (36.2)   61 (38.6)    0.69^d^      20 (27)     41 (49)   0.005^b^
  Oligoprogression                           57 (54.3)   79 (50.0)    0.50^b^      38 (51)     41 (49)   0.75^b^
  CBPD                                                                                                   
   Yes                                       36 (34.3)   50 (31.6)    0.65^b^      14 (19)     36 (43)   0.001^b^
   Median duration (days)                    101         79.5         0.36^a^      44.5        142.5     0.10^a^

ALKi = ALK inhibitor; PS = performance status; CBPD = crizotinib beyond progressive disease; PFS = progression-free survival.

^a^Student\'s t-test of comparison of the mean.

^b^Chi-squared test of general association.

^c^Fisher\'s exact test of general association when sample size requirement for chi-squared test was not matched.

^d^Includes large-cell and other types of carcinoma.

Median post-PD survival was 6.5 months (95% CI: 5.3-9.8). Multivariable Cox regression (Table [6](#T6){ref-type="table"}) revealed that next-generation ALKis and CBPD were associated with improved survival from the first crizotinib dose, as well as improved post-PD survival, as were baseline PS 0-1, PFS with crizotinib ≥median, cerebral progression, and oligoprogression. Subsequent treatment other than next-generation ALKis did not improve survival. BSC only was associated with worse survival from the first crizotinib dose and worse post-PD survival.

###### Cox multivariate analysis\* of survival from the first crizotinib dose and post-progressive disease survival in the population of patients with documented progressive disease on crizotinib (n=263)

  Variable                                                      Tested    Reference   Multivariable analysis                                   
  ------------------------------------------------------------- --------- ----------- ------------------------ ----------- ------------------- -----------
  PS                                                            0-1       2-4         0.49 (0.34--0.70)        p\<0.0001   0.43 (0.30--0.62)   p\<0.0001
  PFS with crizotinib                                           ≥median   \<median    0.28 (0.20--0.40)        p\<0.0001   0.68 (0.48--0.95)   0.02
  Cerebral progression                                          Yes       No          0.55 (0.39--0.77)        0.0006      0.67 (0.49--0.94)   0.02
  Oligoprogression                                              Yes       No          0.63 (0.46--0.87)        0.005       0.60 (0.44--0.83)   0.002
  Crizotinib beyond PD                                          Yes       No          0.52 (0.35--0.77)        0.001       0.46 (0.31--0.68)   p\<0.0001
  Systemic treatment after progression on crizotinib:                                                                                          
   BSC only                                                     Yes       No          2.06 (1.45--2.93)        \<0.0001    2.39 (1.67--3.42)   \<0.0001
  Subsequent systemic treatment but no next- generation ALKis   Yes       No          (--)                     NS          (--)                NS
   Next-generation ALKis                                        Yes       No          0.34 (0.21--0.55)        \<0.0001    0.36 (0.23--0.57)   \<0.0001

PD = progressive disease; HR = hazard ratio; CI = confidence interval; PS = performance status; PFS = progression-free survival; BSC = best supportive care; ALKi = ALK inhibitor; NS = not significant.

\*The full Cox univariate and multivariate proportional hazard ratio analysis is provided in [Supplementary Table 3](#SD1){ref-type="supplementary-material"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}.

For patients receiving next-generation ALKis, median OS from the first crizotinib dose was not reached (Figure [3A](#F3){ref-type="fig"}). The 1- and 3-year survival rates from the first crizotinib dose were 92.9% (95% CI: 87.3-98.4) and 59.2% (95% CI: 46.4-72.1), respectively. Post-PD survival was significantly longer for patients receiving next-generation ALKis than either those receiving subsequent drugs other than next-generation ALKis or those receiving BSC only (25.0 months \[95% CI: 18.6-NR\] versus 6.4 months \[95% CI: 5.1-10.2\] versus 1.5 \[95% CI: 0.8-2.1\], log rank p=0.0002) (Figure [3B](#F3){ref-type="fig"}).

![Overall survival according to subsequent systemic treatments initiated after progression on crizotinib in patients with documented progressive disease on crizotinib (n=263)\
**A**. Overall survival from the first crizotinib dose and **B**. survival post-progressive disease on crizotinib for the 84 patients receiving next-generation ALK inhibitors after progression on crizotinib, compared with the 74 patients receiving subsequent treatments other than next-generation ALK inhibitors and the 105 patients receiving best supportive care only. **C**. Overall survival from the diagnosis of metastatic disease in the 84 patients receiving next-generation ALK inhibitors after progression on crizotinib.](oncotarget-08-21903-g003){#F3}

The median OS from diagnosis of metastatic disease was 89.6 months (95% CI: 53.5-not reached) for patients receiving next-generation ALKi and significantly longer than either those receiving subsequent drugs other than next-generation ALKi (28.2 months \[95% CI: 22.1-33.0\]) or those receiving BSC only (19.6 months \[95% CI: 15.1-24.5\]) (log rank *P*\<0.001) (Figure [3C](#F3){ref-type="fig"}).

DISCUSSION {#s3}
==========

Our findings provide a robust OS estimation for patients receiving crizotinib for advanced *ALK*-positive NSCLC primarily pretreated with first-line platinum-based regimens. Additionally, our analysis of systemic treatments following disease progression on crizotinib suggests that next-generation ALKis substantially prolong survival after crizotinib failure in comparison with other treatment strategies.

We report a median OS of 16.6 months after initiation of crizotinib, which is slightly shorter than the previous estimation of 21.7 months reported by the PROFILE 1007 trial evaluating crizotinib in the second-line setting. This could be the result of selecting patients in clinical trials compared to all-comer patients treated in daily practice. Our patients were older, less commonly women and non-smokers, with poorer PS than those enrolled in PROFILE 1007 \[[@R4]\]. In 40.9% of cases, patients received more than one systemic treatment before crizotinib and were less able to receive subsequent treatments, though the line of crizotinib treatment did not impact survival outcomes on crizotinib in our study. Almost all were of non-Asian ethnicity, compared to 54% of the patients in PROFILE 1007 \[[@R4]\]. A non-Asian ethnicity-related negative effect on outcome could not be excluded \[[@R23]\].

Current smoking at time of crizotinib initiation had a strong negative effect on survival outcomes. *ALK* rearrangement is detected in higher proportions in non-smokers and former smokers \[[@R1]\]. Very few current smokers were enrolled in clinical trials with crizotinib, meaning little is known about crizotinib efficacy in this patient subset \[[@R3], [@R4]\]. The current-smoker population could consist of those with very poor prognosis and a specific biological pattern, explaining the lack of efficacy of crizotinib. Furthermore, cigarette smoking induces cytochromes CYP1A1/1A2 and is hypothesized to alter anti-EGFR erlotinib pharmacokinetics, resulting in worse clinical outcomes \[[@R24], [@R25]\]. Crizotinib elimination via CYP1A1/1A2 has not been reported, yet our data suggests cigarette smoking has a potential impact on its pharmacokinetics \[[@R26], [@R27]\]. Nevertheless, only 29 patients were current smokers at time of crizotinib initiation in our study. Our results warrant validation in a larger cohort. On the other hand, PS 2-4 at time of crizotinib initiation was associated with worse survival with crizotinib and after disease progression. This suggests that ALKis should be given to *ALK*-positive patients as soon as possible in the disease course.

CBPD was associated with remarkably similar survival outcomes to those previously reported by Ou *et al*. \[[@R9]\]. CLINALK and Ou *et al*. studies reported median OS with crizotinib of 32.2 and 29.6 months in the CBPD population and 11.2 and 10.8 months in non-CBPD, respectively \[[@R9]\]. The similar survival benefit we observed with CBPD in two independent cohorts, and persistence of this benefit following adjustment for the different systemic treatment strategies initiated after disease progression on crizotinib, confirm the validity of this approach, previously legitimised by the lack of effective and well-tolerated drugs available for strategies following crizotinib failure. Next-generation ALKis have emerged as the preferred treatment in this setting due to their ability to overcome crizotinib resistance. In our study, they deeply impacted survival outcomes when given after disease progression on crizotinib, whereas other systemic treatments did not and, as expected, BSC only was associated with worse survival.

Given its retrospective nature, this survival analysis had several limitations. We included patients receiving crizotinib at different times in their disease course, in second- or third-line in 72.7% of the cases. The survival analysis focused on three non-randomized and unmatched groups of patients according to systemic treatment received after disease progression on crizotinib. As a result, the characteristics of these three groups are partially imbalanced, with biases in patient selection potentially causing the improved survival observed in those receiving CBPD or next-generation ALKis. Alternatively, this could also be due to specific tumour biology and high sensitivity to ALK inhibition, rather than a direct effect of treatment strategies. Patients received next-generation ALKis as clinical trial participants, all with good prognosis. Finally, locally-ablative treatments in cases of oligoprogressive disease were not recorded, potentially causing a partial bias in our results.

Nevertheless, we provide an estimation of survival benefit with next-generation ALKis adjusted for potential confounding factors, including patterns of progression on crizotinib and CBPD, compared to a population treated with systemic treatments other than next-generation ALKis or BSC only. A recently published retrospective analysis of 73 patients treated with crizotinib then ceritinib reported a 49.4-month OS from diagnosis of metastatic disease, though did not provide a comparator population \[[@R20]\]. Two smaller studies with 11 and 13 patients treated with crizotinib then reported good survival outcomes \[[@R21], [@R22]\]. In our study, the 84 patients receiving next-generation ALKis after crizotinib achieved an 89.6-month OS from diagnosis of metastatic disease, with a 59.2% 3-year survival from the first crizotinib dose and median post-PD survival of 25.0 months. The survival rates reported here in a large population treated with crizotinib then next-generation ALKis could represent an interesting benchmark for ongoing clinical trials assessing how best to sequence the available ALKis. The ALEX trial (NCT02075840) is comparing crizotinib and alectinib in first-line setting with no crossover at time of progression. In contrast, the NCI ALK Master Protocol (NCT02465060) will compare in first-line a standard treatment arm with crizotinib to several next-generation ALKis and evaluate different sequential strategies by incorporating systematic crossover in each treatment arm.

In conclusion, the prolonged survival observed in crizotinib clinical trials in *ALK*-positive NSCLC can also be observed in less selective patient populations treated in routine practice. The remarkable median survival from diagnosis of metastatic disease of 89.6 months reported in patients treated with next-generation ALKis after crizotinib emphasizes the importance of accelerated access to diagnostic tools and targeted therapy in molecularly-defined populations. While this study was unable to resolve the question of how best to sequence ALKis, it could provide a rationale that supports the use of sequential ALKis rather than non-targeted treatment after crizotinib failure, along with offering an historical benchmark for the ongoing clinical trials in this setting.

MATERIALS AND METHODS {#s4}
=====================

Study population and procedures {#s4_1}
-------------------------------

This retrospective study included only patients with diagnosis of *ALK*-rearranged NSCLC determined by fluorescent *in situ* hybridization (FISH, performed on a routine basis at certified molecular genetics French National Cancer Institute \[INCa\] platforms using a certified break-apart FISH assay), with advanced/metastatic NSCLC, aged ≥18 years, not enrolled in a crizotinib trial, having received at least 7 days of crizotinib treatment. All received 250mg oral crizotinib twice daily at initiation.

The French crizotinib expanded access program (EAP) enrolled 313 patients exhibiting any *ALK*-positive tumours from November 18^th^ 2010 to October 23^th^ 2012. The EAP database was provided by Pfizer. Of the 117 identified investigational centres, 80 agreed to participate. After EAP discontinuation, we enrolled patients receiving second-line crizotinib as approved drug until December 31^th^ 2013 at participating centres.

Data and survival follow-up were extracted from medical records by investigators in each centre and documented in a standard case report form. Database is held by the French Collaborative Thoracic Intergroup (IFCT) that ensured the quality of the data collected by monitoring the centres via periodic visits of IFCT clinical research associates. Medical monitoring was performed by two co-authors (MD, DMS). The source documents proving the collected data\'s integrity are filed at the investigational centre.

Definitions and study endpoints {#s4_2}
-------------------------------

The sites where PD manifested were reported. Oligoprogressive disease was defined as progression in only one site. CBPD was defined as continuing crizotinib for over 21 days following RECIST-defined PD and best response to crizotinib other than PD. First-line and second-line drugs following crizotinib failure and corresponding response according to RECIST 1.1. were monitored. Crizotinib rechallenge was defined as crizotinib initiation following at least one systemic therapy following PD under crizotinib \[[@R28]\].

The primary end-point was OS measured from the date of first crizotinib dose. Secondary endpoints included: objective response rate (ORR) according to RECIST 1.1, evaluated by investigators; disease control rate (DCR); PFS, according to RECIST 1.1.; OS from PD under crizotinib (post-PD survival); OS from diagnosis of metastatic disease.

Study oversight {#s4_3}
---------------

This non-interventional study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, approved by a national ethics committee, French Advisory Committee on Information Processing in Material Research in the Field of Health, and France\'s national data protection authority (CNIL). All participating departments approved the study protocol. All included patients still alive received information from their referring physician.

Statistical analysis {#s4_4}
--------------------

Variable characteristics were compared with the chi-squared or Fisher\'s exact tests for qualitative variables and Student\'s t-test or ANOVA for quantitative variables. The Kaplan-Meier method was used to estimate all OS endpoints. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) using a Cox model. Univariate Cox models were applied to select the most promising prognostic variables (threshold p=0.20). A multivariate Cox model was then applied using a backwards procedure to adjust for potential confounders. OS was defined as the date of first crizotinib dose to death or final follow-up. Post-PD survival was defined as the date of RECIST-defined PD under crizotinib to death or final follow-up. The cut-off for survival analysis was July 31^st^ 2015. All statistical tests were two-sided, and a p value \<0.05 was deemed statistically significant. All analyses were performed using SAS software, Version 9.3 (SAS Institute).
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